Role of the drug mannitol during operation involving removal of a part of the kidney

Role of intravenous mannitol in patients undergoing laparoscopic nephron-sparing surgery â?? A randomized double-blinded trial. - MINSS

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/026081

Enrollment

Registered

2020-06-23

Start date

Unknown

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C649- Malignant neoplasm of unspecifiedkidney, except renal pelvis

Interventions

Intervention1: Mannitol: 20% mannitol will be administered at a dose of 0.25g/kg intravenously, 30 mins prior to clamping the renal artery Control Intervention1: Placebo - Normal saline: 0.9% NS will

Eligibility

Inclusion criteria

Inclusion criteria: Scheduled for laparoscopic partial nephrectomy at CMC Vellore Preoperative eGFR > 45 ml per min per m2

Exclusion criteria

Exclusion criteria: Known allergy to mannitol Combined major surgery along with partial nephrectomy Solitary functioning kidney Patient with poor LV function Conversion to open.

Design outcomes

Primary

Measure	Time frame
To establish equivalence of eGFR at 6 months after laparoscopic partial nephrectomy between mannitol group and the placebo group.Timepoint: 6 months	—

Secondary

Measure	Time frame
Compare blood lossTimepoint: Intraoperative;Compare grade 3-5 complications (clavien-dindo)Timepoint: At the time of discharge. Day 3;Compare intraoperative ischemia timeTimepoint: Intraoperative;Difference in eGFR Timepoint: Postoperative Day 2 and Day 10	—

Countries

India

Contacts

Public ContactAbhilash Cheriyan

Christian Medical College and Hospital

nirmaltj@cmcvellore.ac.in04162282111

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026